Pharmaceutical Licensing Market Led By AstraZeneca, GSK Merck, Novartis, Pfizer and Roche: companiesandmarkets.com

LONDON--(BUSINESS WIRE)-- Pharmaceutical licensing agreements are proving to be a cost-effective way of acquiring new molecules for drug discovery and development, according to a new report available on companiesandmarkets.com. Most pharmaceutical in-licensing activity is conducted by large pharmaceutical companies who are in a strong position to commercialize novel therapeutics.

Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity

http://www.companiesandmarkets.com/Market-Report/licensing-strategies-of-large-pharmaceutical-companies-weak-rd-pipelines-and-the-patent-cliff-stimulate-in-licensing-activity-686522.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

Research and development in the pharmaceutical industry is incredibly expensive and time consuming, therefore pharmaceutical companies are constantly seeking ways of cutting costs and speeding up the process. By in-licensing potential products, pharmaceutical companies can compensate for reduced expenditure on R&D, while also offsetting the limitations of their existing product pipelines which have been subdued by budgetary restraints in recent years.

By acquiring the rights to novel molecules developed by universities and small companies - or the companies themselves in some instances - large pharmaceutical companies are able to remain competitive and minimise the risk of failure associated with drug development.

2012 marks the year in which a number of blockbuster patents will expire, leaving several pharmaceutical companies in a vulnerable position as generic alternatives encroach on their market share.

In-licensing also provides pharmaceutical companies with the opportunity to enter into markets where they have no existing presence, or present distinct opportunities for growth. The unmet need within the oncology/cancer market is particularly attractive to big pharma, as is the monoclonal antibodies segment.

Published in September 2011, the report provides 153 pages of pharmaceutical licensing analysis, split by value, type, geography, therapy area and phase for the period 2006-2010. The report discusses the licensing lifecycle, in-licensing and out-licensing trends, important deals and the drivers which encourage licensing activity in the pharmaceutical sector.

The pharmaceutical licensing activities of the following companies are examined at length within this report: GlaxoSmithKline; J&J Roche; Abbott; Eli Lilly; Novartis; Sanofi; Takeda; Pfizer; Bristol-Myers Squibb; Boehringer-Ingelheim; Merck & Co.; Bayer; AstraZeneca; Astellas; Daiichi-Sankyo; Teva Pharma; Eisai; Baxter and Amgen.

Report Details:

http://www.companiesandmarkets.com/Market-Report/licensing-strategies-of-large-pharmaceutical-companies-weak-rd-pipelines-and-the-patent-cliff-stimulate-in-licensing-activity-686522.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Paul Chapman
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Practice Management  Health  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.